Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials

J Nucl Med. 2006 Jun;47(6):1059-66.

Authors

Lalitha K Shankar¹, John M Hoffman, Steve Bacharach, Michael M Graham, Joel Karp, Adriaan A Lammertsma, Steven Larson, David A Mankoff, Barry A Siegel, Annick Van den Abbeele, Jeffrey Yap, Daniel Sullivan; National Cancer Institute

Affiliation

¹ Cancer Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA. [email protected]

PMID: 16741317

No abstract available

Publication types

Consensus Development Conference, NIH
Practice Guideline

MeSH terms

Clinical Trials as Topic / standards*
Fluorodeoxyglucose F18*
Humans
National Institutes of Health (U.S.)
Neoplasms / diagnostic imaging*
Neoplasms / therapy*
Outcome Assessment, Health Care / methods*
Outcome Assessment, Health Care / standards*
Positron-Emission Tomography / methods
Positron-Emission Tomography / standards*
Prognosis
Radiopharmaceuticals
Treatment Outcome
United States

Substances

Radiopharmaceuticals
Fluorodeoxyglucose F18